S4. HORMONE AND METABOLIC MODULATORS
PROHIBITED AT ALL TIMES (IN- AND OUT-OF-COMPETITION)
Prohibited substances in classes S4.1 and S4.2 are Specified Substances. Those in classes S4.3 and S4.4 are non-Specified Substances.
The following hormone and metabolic modulators are prohibited:
S4.1. AROMATASE INHIBITORS
Including, but not limited to:
- 2-Androstenol (5ɑ-androst-2-en-17-ol)
- 2-Androstenone (5ɑ-androst-2-en-17-one)
- 3-Androstenol (5ɑ-androst-3-en-17-ol)
- 3-Androstenone (5ɑ-androst-3-en-17-one)
- 4-Androstene-3,6,17 trione (6-oxo)
- Aminoglutethimide
- Anastrozole
- Androsta-1,4,6-triene-3,17-dione (androstatrienedione)
- Androsta-3,5-diene-7,17-dione (arimistane)
- Exemestane
- Formestane
- Letrozole
- Testolactone
S4.2. ANTI-ESTROGENIC SUBSTANCES [ANTI-ESTROGENS AND SELECTIVE ESTROGEN RECEPTOR MODULATORS (SERMS)]
Including, but not limited to:
- Bazedoxifene
- Clomifene
- Cyclofenil
- Fulvestrant
- Ospemifene
- Raloxifene
- Tamoxifen
- Toremifene
S4.3. AGENTS PREVENTING ACTIVIN RECEPTOR IIB ACTIVATION
Including, but not limited to:
- Activin A-neutralizing antibodies
- Activin receptor IIB competitors such as:
- Decoy activin receptors (e.g. ACE-031)
- Anti-activin receptor IIB antibodies (e.g. bimagrumab)
- Myostatin inhibitors such as:
- Agents reducing or ablating myostatin expression
- Myostatin-binding proteins (e.g. follistatin, myostatin propeptide)
- Myostatin- or precursor-neutralizing antibodies (e.g. apitegromab, domagro- zumab, landogrozumab, stamulumab)
S4.4. METABOLIC MODULATORS
S4.4.1 Activators of the AMP-activated protein kinase (AMPK), e.g. AICAR; peroxisome proliferator-activated receptor delta (PPARδ) agonists, e.g. 2-(2-methyl-4-((4-methyl-2-(4-(trifluoromethyl)phenyl)thiazol-5-yl)methylthio) phenoxy) acetic acid (GW1516, GW501516) and Rev-erbɑ agonists, e.g. SR9009, SR9011
S4.4.2 Insulins and insulin-mimetics
S4.4.3 Meldonium
S4.4.4 Trimetazidine